Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study

Andreas Ronit; Shweta Sharma; Jason V. Baker; Rosie Mngqibisa; Tristan Delory; Luis Caldeira; Nicaise Ndembi; Jens D. Lundgren; Andrew N. Phillips

doi:10.1093/infdis/jix350

Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study

Andreas Ronit, Shweta Sharma, Jason V. Baker, Rosie Mngqibisa, Tristan Delory, Luis Caldeira, Nicaise Ndembi, Jens D. Lundgren, Andrew N. Phillips

Biostatistics

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Background. Serum albumin may be used to stratify human immunodeficiency virus (HIV)-infected persons with high CD4 count according to their risk of serious non-AIDS endpoints. Methods. Cox proportional hazards models were used to analyze the risk of serious non-AIDS events in the Strategic Timing of Antiretroviral Treatment (START) study (NCT00867048) with serum albumin as a fixed and time-updated predictor. Models with exclusion of events during initial follow-up years were built to assess the ability of serum albumin to predict beyond shorter periods of time. Secondarily, we considered hospitalizations and AIDS events. Results. Among 4576 participants, 71 developed a serious non-AIDS event, 788 were hospitalized, and 63 experienced an AIDS event. After adjusting for a range of variables associated with hypoalbuminemia, higher baseline serum albumin (per 1 g/dL) was associated with a decreased risk of serious non-AIDS events (hazard ratio, 0.37 [95% confidence interval, .20-.71]; P = .002). Similar results were obtained in a time-updated model, after controlling for interleukin 6, and after excluding initial follow-up years. Serum albumin was independently associated with hospitalization but not with risk of AIDS. Conclusions. A low serum albumin level is a predictor for short-A nd long-term serious non-AIDS events, and may be a useful marker of risk of noncommunicable diseases, particularly in resource-limited settings.

Original language	English (US)
Pages (from-to)	405-412
Number of pages	8
Journal	Journal of Infectious Diseases
Volume	217
Issue number	3
DOIs	https://doi.org/10.1093/infdis/jix350
State	Published - Jan 17 2018

Bibliographical note

Funding Information:
Financial support. This work was supported by the National Institute of Allergy and Infectious Diseases; National Institutes of Health Clinical Center; National Cancer Institute; National Heart, Lung, and Blood Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (France); National Health and Medical Research Council (Australia); National Research Foundation (Denmark); Bundesministerium für Bildung und Forschung (Germany); European AIDS Treatment Network; Medical Research Council, National Institute for Health Research, and National Health Service (United Kingdom); and University of Minnesota. National Institute of Health grant numbers for START: UM1-AI068641 and UM1-AI120197. Antiretroviral drugs were donated to the central drug repository by AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Janssen Scientific Affairs, and Merck.

Publisher Copyright:
© 2017 The Author(s).

Keywords

HIV
albumin
biomarker
non-AIDS comorbidity
non-communicable disease

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1093/infdis/jix350

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853310

OpenUrl availability

Full text

Cite this

@article{4255fc0b3d6a4cfcaf65497866a28a68,

title = "Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study",

abstract = "Background. Serum albumin may be used to stratify human immunodeficiency virus (HIV)-infected persons with high CD4 count according to their risk of serious non-AIDS endpoints. Methods. Cox proportional hazards models were used to analyze the risk of serious non-AIDS events in the Strategic Timing of Antiretroviral Treatment (START) study (NCT00867048) with serum albumin as a fixed and time-updated predictor. Models with exclusion of events during initial follow-up years were built to assess the ability of serum albumin to predict beyond shorter periods of time. Secondarily, we considered hospitalizations and AIDS events. Results. Among 4576 participants, 71 developed a serious non-AIDS event, 788 were hospitalized, and 63 experienced an AIDS event. After adjusting for a range of variables associated with hypoalbuminemia, higher baseline serum albumin (per 1 g/dL) was associated with a decreased risk of serious non-AIDS events (hazard ratio, 0.37 [95% confidence interval, .20-.71]; P = .002). Similar results were obtained in a time-updated model, after controlling for interleukin 6, and after excluding initial follow-up years. Serum albumin was independently associated with hospitalization but not with risk of AIDS. Conclusions. A low serum albumin level is a predictor for short-A nd long-term serious non-AIDS events, and may be a useful marker of risk of noncommunicable diseases, particularly in resource-limited settings.",

keywords = "HIV, albumin, biomarker, non-AIDS comorbidity, non-communicable disease",

author = "Andreas Ronit and Shweta Sharma and Baker, {Jason V.} and Rosie Mngqibisa and Tristan Delory and Luis Caldeira and Nicaise Ndembi and Lundgren, {Jens D.} and Phillips, {Andrew N.}",

note = "Funding Information: Financial support. This work was supported by the National Institute of Allergy and Infectious Diseases; National Institutes of Health Clinical Center; National Cancer Institute; National Heart, Lung, and Blood Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Agence Nationale de Recherches sur le SIDA et les H{\'e}patites Virales (France); National Health and Medical Research Council (Australia); National Research Foundation (Denmark); Bundesministerium f{\"u}r Bildung und Forschung (Germany); European AIDS Treatment Network; Medical Research Council, National Institute for Health Research, and National Health Service (United Kingdom); and University of Minnesota. National Institute of Health grant numbers for START: UM1-AI068641 and UM1-AI120197. Antiretroviral drugs were donated to the central drug repository by AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Janssen Scientific Affairs, and Merck. Publisher Copyright: {\textcopyright} 2017 The Author(s).",

year = "2018",

month = jan,

day = "17",

doi = "10.1093/infdis/jix350",

language = "English (US)",

volume = "217",

pages = "405--412",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study

AU - Ronit, Andreas

AU - Sharma, Shweta

AU - Baker, Jason V.

AU - Mngqibisa, Rosie

AU - Delory, Tristan

AU - Caldeira, Luis

AU - Ndembi, Nicaise

AU - Lundgren, Jens D.

AU - Phillips, Andrew N.

N1 - Funding Information: Financial support. This work was supported by the National Institute of Allergy and Infectious Diseases; National Institutes of Health Clinical Center; National Cancer Institute; National Heart, Lung, and Blood Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (France); National Health and Medical Research Council (Australia); National Research Foundation (Denmark); Bundesministerium für Bildung und Forschung (Germany); European AIDS Treatment Network; Medical Research Council, National Institute for Health Research, and National Health Service (United Kingdom); and University of Minnesota. National Institute of Health grant numbers for START: UM1-AI068641 and UM1-AI120197. Antiretroviral drugs were donated to the central drug repository by AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Janssen Scientific Affairs, and Merck. Publisher Copyright: © 2017 The Author(s).

PY - 2018/1/17

Y1 - 2018/1/17

N2 - Background. Serum albumin may be used to stratify human immunodeficiency virus (HIV)-infected persons with high CD4 count according to their risk of serious non-AIDS endpoints. Methods. Cox proportional hazards models were used to analyze the risk of serious non-AIDS events in the Strategic Timing of Antiretroviral Treatment (START) study (NCT00867048) with serum albumin as a fixed and time-updated predictor. Models with exclusion of events during initial follow-up years were built to assess the ability of serum albumin to predict beyond shorter periods of time. Secondarily, we considered hospitalizations and AIDS events. Results. Among 4576 participants, 71 developed a serious non-AIDS event, 788 were hospitalized, and 63 experienced an AIDS event. After adjusting for a range of variables associated with hypoalbuminemia, higher baseline serum albumin (per 1 g/dL) was associated with a decreased risk of serious non-AIDS events (hazard ratio, 0.37 [95% confidence interval, .20-.71]; P = .002). Similar results were obtained in a time-updated model, after controlling for interleukin 6, and after excluding initial follow-up years. Serum albumin was independently associated with hospitalization but not with risk of AIDS. Conclusions. A low serum albumin level is a predictor for short-A nd long-term serious non-AIDS events, and may be a useful marker of risk of noncommunicable diseases, particularly in resource-limited settings.

AB - Background. Serum albumin may be used to stratify human immunodeficiency virus (HIV)-infected persons with high CD4 count according to their risk of serious non-AIDS endpoints. Methods. Cox proportional hazards models were used to analyze the risk of serious non-AIDS events in the Strategic Timing of Antiretroviral Treatment (START) study (NCT00867048) with serum albumin as a fixed and time-updated predictor. Models with exclusion of events during initial follow-up years were built to assess the ability of serum albumin to predict beyond shorter periods of time. Secondarily, we considered hospitalizations and AIDS events. Results. Among 4576 participants, 71 developed a serious non-AIDS event, 788 were hospitalized, and 63 experienced an AIDS event. After adjusting for a range of variables associated with hypoalbuminemia, higher baseline serum albumin (per 1 g/dL) was associated with a decreased risk of serious non-AIDS events (hazard ratio, 0.37 [95% confidence interval, .20-.71]; P = .002). Similar results were obtained in a time-updated model, after controlling for interleukin 6, and after excluding initial follow-up years. Serum albumin was independently associated with hospitalization but not with risk of AIDS. Conclusions. A low serum albumin level is a predictor for short-A nd long-term serious non-AIDS events, and may be a useful marker of risk of noncommunicable diseases, particularly in resource-limited settings.

KW - HIV

KW - albumin

KW - biomarker

KW - non-AIDS comorbidity

KW - non-communicable disease

UR - http://www.scopus.com/inward/record.url?scp=85041182880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041182880&partnerID=8YFLogxK

U2 - 10.1093/infdis/jix350

DO - 10.1093/infdis/jix350

M3 - Article

C2 - 29244111

AN - SCOPUS:85041182880

SN - 0022-1899

VL - 217

SP - 405

EP - 412

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 3

ER -

Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this